Tentt

Firefly Bio Acquired by Johnson & Johnson | Healthcare M&A Deal

Announced
HealthcarePlatform

Deal Overview

Johnson & Johnson has acquired Firefly Bio, a medical devices business in cash, for $1B. Firefly Bio develops “degrader-antibody conjugates” that combine protein degrader compounds with antibody-drug conjugate concepts for targeted cancer therapy. Johnson & Johnson acquisitions aim to strengthen its oncology portfolio by improving payload release and linker stability versus traditional ADC limitations. The Johnson & Johnson acquisitions are a strategic platform acquisition announced in 2026, with Firefly Bio founded in 2022 and backed by nearly $100 million in venture funding.

Key Details

Transaction
Johnson & Johnson acquires Firefly Bio
Deal Size
Over $100M
Reported Value
$1B

Filed under

Source

Read full article on biopharmadive.com

via BioPharma Dive · June 8, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call

Related Deals

See all Healthcare deals →